2171 — CARsgen Therapeutics Holdings Share Price
0.000.00%
Last trade - 00:00- HK$8.82bn
- HK$7.42bn
- CNY39.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.84 | ||
| Price to Tang. Book | 7.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 210.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.95% | ||
| Return on Equity | -55.84% | ||
| Operating Margin | -2049.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 25.81 | n/a | n/a | 39.42 | 118.49 | 370.14 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
Directors
- Zonghai Li CHM
- Huamao Wang COO
- Lan Xie SVF
- Yong Fan SVP
- Leigh Hsu SVP
- Hong Ma SVP (50)
- Jie Jia VOP (43)
- Wei Wang VPR (46)
- Wing Yat Lui SEC
- Bingsen Guo NED (50)
- Huaqing Guo NED (32)
- Ronggang Xie NED (36)
- Yachao Zhao NED (39)
- Chunhai Fan NID (47)
- Tak Young So NID (50)
- Guangmei Yan NID (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 9th, 2018
- Public Since
- June 18th, 2021
- No. of Employees
- 468
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 572,656,931
- Address
- Building 12, SHANGHAI, KY1-1205
- Web
- https://www.carsgen.com/
- Phone
- Auditors
- Ernst & Young
Upcoming Events for 2171
CARsgen Therapeutics Holdings Ltd Annual Shareholders Meeting
Similar to 2171
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the CARsgen Therapeutics Holdings share price?
As of Today at 19:48 UTC, shares in CARsgen Therapeutics Holdings are trading at HK$15.40. This share price information is delayed by 15 minutes.
How has the CARsgen Therapeutics Holdings share price performed this year?
Shares in CARsgen Therapeutics Holdings last closed at HK$15.40 and the price had moved by +188.93% over the past 365 days. In terms of relative price strength the CARsgen Therapeutics Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +192.23% over the past year.
What are the analyst and broker recommendations for CARsgen Therapeutics Holdings?
The overall consensus recommendation for CARsgen Therapeutics Holdings is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CARsgen Therapeutics Holdings dividend yield?
CARsgen Therapeutics Holdings does not currently pay a dividend.
Does CARsgen Therapeutics Holdings pay a dividend?
CARsgen Therapeutics Holdings does not currently pay a dividend.
When does CARsgen Therapeutics Holdings next pay dividends?
CARsgen Therapeutics Holdings does not currently pay a dividend.
How do I buy CARsgen Therapeutics Holdings shares?
To buy shares in CARsgen Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CARsgen Therapeutics Holdings?
As of the previous close price of HK$15.40, shares in CARsgen Therapeutics Holdings had a market capitalisation of HK$8.82bn.
Where are CARsgen Therapeutics Holdings shares listed?
Here are the trading details for CARsgen Therapeutics Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2171
What kind of share is CARsgen Therapeutics Holdings?
Based on an overall assessment of its quality, value and momentum CARsgen Therapeutics Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CARsgen Therapeutics Holdings share price forecast for 2025?
The analyst consensus target price for shares in CARsgen Therapeutics Holdings is HK$9.07. That is 41.08% below the last closing price of HK$15.40.
Analysts covering CARsgen Therapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.81 for the next financial year.
Find out moreWhat is the trend in the CARsgen Therapeutics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CARsgen Therapeutics Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +293.21%.
As of the last closing price of HK$15.40, shares in CARsgen Therapeutics Holdings were trading +96.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CARsgen Therapeutics Holdings PE Ratio?
The CARsgen Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$15.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CARsgen Therapeutics Holdings?
CARsgen Therapeutics Holdings' management team is headed by:
- Zonghai Li - CHM
- Huamao Wang - COO
- Lan Xie - SVF
- Yong Fan - SVP
- Leigh Hsu - SVP
- Hong Ma - SVP
- Jie Jia - VOP
- Wei Wang - VPR
- Wing Yat Lui - SEC
- Bingsen Guo - NED
- Huaqing Guo - NED
- Ronggang Xie - NED
- Yachao Zhao - NED
- Chunhai Fan - NID
- Tak Young So - NID
- Guangmei Yan - NID